Featured News
Expedite Your Program with the eXpDNA™ Plasmid Platform
Universal plasmid platform proven to reduce production timelines and streamline development pathways
Focused on speed and product quality, eXpDNA™ supports your plasmid strategy by offering a universal, standardized platform to streamline development and cut production timelines to as little as five weeks.
“eXpDNA is at the nucleus of our plasmid production offering,” explains Andrew Frazer, PhD, Associate Director, Scientific Solutions, Gene Therapy CDMO Services. “The significant turnaround time reduction for clients leveraging the platform, combined with Charles River’s established CDMO capabilities and phase-appropriate approach, will help to both accelerate timelines and ensure the highest quality product.”
Fine-tuned by successfully supporting vaccine and advanced therapy medicinal product (ATMP) clients in the development, manufacture, and release of more than 200 High Quality (HQ) and Good Manufacturing Practices (GMP) plasmid DNA batches to date, eXpDNA consists of an efficient and robust plug-n-play screening toolbox for tackling challenging plasmids, phase-appropriate production with fit-for-purpose facilities, on-hand materials, and in-house analytics. The platform, in combination with a significant capacity expansion, expedites batch turnaround times to as few as five weeks for HQ and ten weeks for GMP grade to serve growing global demand.
eXpDNA™ Platform Launch: On-Demand
Debuted at Advanced Therapies Week, join Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services, to explore the platform and discover the key benefits to gene therapy developers.
View Now
Launch at Phacilitate Advanced Therapies Week
“The launch of Charles River’s eXpDNA plasmid manufacturing platform is the latest in a series of portfolio enhancements aimed at supporting vaccine and advanced therapy clients through clinical trials and beyond,” commented Kerstin Dolph, Corporate Senior Vice President, Biologics Solutions, in a press release announcing the platform. “By increasing speed and efficiency for plasmid DNA production, eXpDNA will help accomplish our ultimate goal of delivering safe, effective therapies to patients faster.”
Officially unveiled during Advanced Therapies Week, January 17 – 20, 2023 in Miami, FL, Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services showcases the key benefits of the platform to cell and gene therapy and vaccine developers alike:
Plug-and-Play Toolbox
Experience with various complex plasmids
Platform Manufacturing Process
20+ years of experience and >95% successfully released pDNA batches
100% In-house Analytics
30+ years of biologics testing experience
For more information on our plasmid DNA and comprehensive cell and gene therapy development and manufacturing services, please visit: Cell and Gene Therapy CDMO Solutions.
Case Study Webinar: Sustainable Plasmid DNA Strategies
Join us and gene therapy developer Purespring Therapeutics to explore common challenges and regulatory guidance for sourcing plasmid DNA to support long-term program delivery and how to set yourself up for success when working with CDMOs.
Watch On Demand